Healthcare - Biotechnology - NASDAQ - US
$ 44.5
-3.8 %
$ 2.12 B
Market Cap
-19.26
P/E
CASH FLOW STATEMENT
-70.9 M
OPERATING CASH FLOW
-107 M
INVESTING CASH FLOW
337 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Mirum Pharmaceuticals, Inc.
| Net Income | -163 M |
| Depreciation & Amortization | 10.8 M |
| Capital Expenditures | -20.1 M |
| Stock-Based Compensation | 35 M |
| Change in Working Capital | -22.6 M |
| Others | 64.2 M |
| Free Cash Flow | -91.1 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (163.4) | (135.7) | (84.0) | (103.3) | (52.6) | (17.3) |
| Depreciation & Amortization | 10.8 | 3.7 | 1.0 | 0.6 | 0.3 | 0 |
| Deferred Income Tax | 0 | (6.6) | 0.6 | 72 K | 0 | 0 |
| Stock Based Compensation | 35.0 | 27.0 | 23.1 | 12.6 | 6.1 | 51 K |
| Other Operating Activities | 69.3 | 12.5 | (90.4) | 0.3 | (0.3) | 12.1 |
| Change in Working Capital | (22.6) | (21.1) | 17.0 | 0.6 | 7.1 | 2.4 |
| Cash From Operations | (70.9) | (120.1) | (132.8) | (89.1) | (39.4) | (0.4) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (20.1) | (0.3) | (19.0) | (0.2) | (0.3) | (7.5) |
| Other Items | (87.1) | 8.0 | 67.6 | 38.1 | (127.5) | 0 |
| Cash From Investing Activities | (107.2) | 7.7 | 48.5 | 37.9 | (127.8) | (7.5) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 109.7 | 0 | 0 | 0 | 0 | 50 K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 10.2 | 1.7 | 66.6 | 49.4 | 60.0 | 0 |
| Cash From Financing Activities | 336.6 | 109.1 | 73.5 | 181.3 | 127.2 | 59.8 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 158.3 | (3.3) | (10.7) | 130.1 | (40.0) | 52.0 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (91.1) | (120.4) | (151.8) | (89.3) | (39.6) | (7.9) |